Round three of IRA negotiations is expected to be ‘manageable’ for pharma

Drugmakers will likely be able to handle the impacts of the third round of Medicare negotiations, analysts say, even as the biopharma industry continues to criticize the Biden-era program. On Tuesday, CMS